Richard David Scheyer MD

PubMed

• 7 citations
  Review of new antiepileptic drugs (AEDs)
  Joyce A. Cramer, Richard H. Mattson, Richard D. Scheyer, Jacqueline A. French
  Epilepsia. 1998-02-01
• 12 citations
  Chapter 23 Involvement of glutamate in human epileptic activities
  Richard D. Scheyer
  Progress in Brain Research. 1998-01-01
• 4 citations
  Novel methods for studying new antiepileptic drug pharmacology
  Richard H. Mattson, Richard D. Scheyer, Ognen A. C. Petroff, M. J. During, T. L. Collins
  Advances in Neurology. 1998-01-01

Journal Articles

• Recommendations from the STAIR V Meeting on acute stroke trials, technology and outcomes  
  Fisher M, Hanley DF, Howard G, Jauch EC, Warach S, STAIR Group (Scheyer RD), Stroke, 1/1/2007
• A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses  
  O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW, Stewart JA, Scheyer R, Neurology, 1/1/2006
• Protein binding and whole blood assays  
  Scheyer RD, Mattson RH, Ther Drug Monit, 1/1/1997
• Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures  
  Mattson RH, Cramer JA, Collins JF, et al, Neurology, 1/1/1996
• Near-patient rapid assay of phenytoin concentrations  
  Scheyer RD, Hochholzer JM, Mattson RH, Epilepsia, 1/1/1995
• Safety of intravenous valproate  
  Devinsky O, Leppik I, Willmore LJ Pellock JM, Dean C, Gates J, and the Intravenous Valproate Study Team (Scheyer RD), Ann Neurol, 1/1/1995
• Near-patient rapid assay of carbamazepine concentrations  
  Scheyer RD, Hochholzer JM, Mattson RH, J Epilepsy, 1/1/1995
• Long-term subdural strip electrocorticographic monitoring of ictal deja vu  
  Scheyer RD, Spencer DD, Spencer SS, Epilepsia, 1/1/1995
• A pharmacodynamic approach to the estimate of carbamazepine autoinduction  
  Scheyer RD, Cramer JA, Mattson RH, and VA Coop Study Group No. 118, J Pharm Sci, 1/1/1994
• Simultaneous HPLC analysis of carbamazepine and carbamazepine epoxide in human brain microdialysate  
  Scheyer RD, During MJ, Cramer JA, Toftness BR, Hochholzer JM, Mattson RH, J Liquid Chromatogr, 1/1/1994
• The long-term safety and efficacy of gabapentin as add-on therapy in drug resistant partial epilepsy  
  The U.S. Gabapentin Study Group (Scheyer RD), Epilepsy Res, 1/1/1994
• Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis  
  Scheyer RD, During MJ, Spencer DD, Cramer JA, Mattson RH, Neurology, 1/1/1994
• Measurement of phenytoin concentrations in the human brain: An in vivo microdialysis study  
  Scheyer RD, During MJ, Hochholzer JM, Spencer DD, Mattson RH, Epilepsy Res, 1/1/1994
• Differentiation of temporal lobe ictal behavior associated with hippocampal sclerosis and tumors of temporal lobe  
  Saygi S, Spencer S, Scheyer R, Katz A, Mattson R, Spencer D, Epilepsia, 1/1/1994
• Gabapentin as add-on therapy in refractory partial epilepsy  
  The U.S. Gabapentin Study Group No. 5, Mclean MJ et al, (Scheyer RD), Neurology, 1/1/1993
• Valproate for treatment of partial and secondarily generalized tonic-clonic seizures in adults: a comparison with carbamazepine  
  Mattson RH, Cramer JA, Collins JF, and the DVA Coop Study Group No. 264 (Scheyer RD), N Engl J Med, 1/1/1992
• A method for prediction of phenytoin levels in the acute clinical setting  
  Scheyer RD, Mattson RH, Comput and Biomed Res, 1/1/1991
• Clinical and electrographic effects of acute anticonvulsant withdrawal in epileptic patients  
  Marks DA, Katz A, Scheyer RD, Spencer SS, Neurology, 1/1/1991
• Compliance declines between clinic visits  
  Cramer JA, Scheyer RD, Mattson RH, Arch Intern Med, 1/1/1990
• Pharmacokinetics of antiepileptic drugs  
  Scheyer RD, Cramer JA, Seminars in Neurology, 1/1/1990
• In vivo determinations of valproate binding constants during sole and multi-drug therapy  
  Scheyer RD, Cramer JA, Toftness BR, Hochholzer JM, Mattson RH, Ther Drug Monit, 1/1/1990
• How often is medication taken as prescribed? A novel assessment technique  
  Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellete VO, JAMA (Journal of the American Medical Association), 1/1/1989
• Pyridoxine in carpal tunnel syndrome  
  Scheyer RD, Haas DC, Lancet, 1/1/1985
• Join now to see all

Books/Book Chapters

• Antiepileptic Drugs 
  Chapter: Valproate: Interactions with other drugs. 
  Page 801 - 807Scheyer RDEditors: Levy RH, Mattson RH, Meldrum BS, Perucca E.Lippincott Williams & Wilkins, New YorkEdition 5th,2002
• Progress in Brain Research Vol. 116: The Glutamate Synapse as a Therapeutical Target: Molecular Organization and Pathology of the Glutamate Synapse 
  Chapter: Involvement of glutamate in human epileptic activities. 
  Page 359 - 369Scheyer RDEditors: Ottersen OP, Langmoen IA, Gjerstad L.Elsevier1998
• Antiepileptic Drug Development 
  Chapter: Novel methods for studying antiepileptic drug pharmacology. 
  Page 105 - 112Mattson RH, Scheyer RD, Petroff OAC, During M, Collins TL, Spencer DEditors: French J, Leppik I, Dichter M.Raven Press, NY1998
• Antiepileptic Drugs 
  Chapter: Potential antiepileptic drugs: Remacemide. 
  Page 1035 - 1044Clark B, Hutchinson JB, Jamieson V, Jones T, Palmer GC, Scheyer RDEditors: Levy RH, Mattson RH, Meldrum BS.Raven Press, New YorkEdition 4th,1995
• Fourth International Symposium on Sodium Valproate and Epilepsy 
  Chapter: Disinduction of valproate metabolism: timing and magnitude of change. A Preliminary report. 
  Page 138 - 142Mattson RH, Cramer JA, Scheyer RD, Hochholzer JMEditors: Chadwick D.Royal Society of Medicine, London1990
• Alcohol and Seizures: Basic Mechanisms and Clinical Concepts 
  Chapter: The effect of alcohol use on antiepileptic drugs. 
  Page 241 - 250Cramer JA, Scheyer RDEditors: RJ Porter, RH Mattson, JA Cramer, I Diamond.F.A. Davis Publishers, Philadelphia1990
• Join now to see all

Abstracts/Posters

• Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
  Moore KN, Bendell JC, Olszanski AJ, Desai M, Jansen M, Scheyer RD, Senaldi G, LoRusso P, J Clin Oncol, 1/1/2013
• A sepsis progression model in humans: Characterization of biomarkers descriptive of sepsis progression.
  Footer BW, Hsiao C-B, Parish DM, Wickremasingha P, Halim A-B, Senaldi G, Scheyer R, Schentag JJ, Critical Care, 1/1/2011
• Immunohistochemical Analysis of HB-EGF Expression in Breast, Colon, Gastric, Hepatocellular, Lung, Ovarian, Pancreatic and Prostate Cancer.
  Halim A-B, Dauffenbach LM, Kerfoot CA, Stull WR, Zwick-Wallasch E, Scheyer R, Senaldi G, Cancer Research, 1/1/2011
• The gastric modifier esomeprazole did not affect the bioavailability and tolerability of CS-7017 in an open-label, phase I, two-way crossover clinical study in healthy...
  Scheyer R, Zahir H, Luo R, He L, Noveck R, Liu K, Eur J Cancer, 1/1/2010
• Food does not affect the pharmacokinetics of CS-7017 in healthy subjects: results from an open label, phase I, two-treatment, three-period, crossover study.
  Scheyer R, Zahir H, Luo R, He L, Noveck R, Liu K, Eur J Cancer, 1/1/2010
• Oral teriflunomide is safe and effective in multiple sclerosis with relapses: Results of a randomized, placebo controlled phase II study.
  Li D, O'Connor P, Freedman M, Bar-Or A, Rice G, Confavreux C, Paty D, Stewart J, Fourre J, Saoud J, Styren S, Scheyer R, Mult Scler, 1/1/2004
• Molecular circadian rhythms in rat-1 fibroblasts I: Developing a high-throughput assay.
  Hurst WJ, Camacho F, Lozada A, Vielhaber E, Friedman E, Scheyer R, Harnish S, Zhang P, Patel K, Errico M, Menaker M, Lenox R, Giovanni A, Society for Neuroscience, 1/1/2003
• Linearity of unbound valproic acid kinetics.
  Scheyer RD, Scheuer ML, Cramer JA, and DVA Cooperative Study Group #264, Epilepsia, 1/1/1997
• Dose-dependency of carbamazepine metabolism in humans.
  Scheuer ML, Scheyer RD, Cramer JA, and DVA Cooperative Study Group #264, Epilepsia, 1/1/1997
• Gabapentin related myoclonus.
  Scheyer RD, Assaf BA, Spencer DD, Mattson RH, Epilepsia, 1/1/1996
• Ictal PET in epilepsy.
  Scheyer RD, Dey HM, Spencer SS, Epilepsia, 1/1/1995
• Pharmacokinetic studies in humans: Brain compartment.
  Scheyer RD, During MJ, Mattson RH, Epilepsia, 1/1/1995
• Elimination of carbamazepine and its metabolites from the human brain: A microdialysis study.
  Scheyer RD, Hochholzer JM, During MJ, Spencer DD, Mattson RH, Epilepsia, 1/1/1994
• Phenytoin concentrations in the human brain: A microdialysis study.
  Scheyer RD, During MJ, Hochholzer JM, Spencer DD, Mattson RH, Epilepsia, 1/1/1993
• Microdialysis measurement of brain entry of carbamazepine and its metabolites.
  Scheyer RD, Mattson RH, During MJ, Hochholzer JM, Toftness BR, Spencer DD, Epilepsia, 1/1/1993
• Temporal lobe ictal behavior associated with hippocampal sclerosis and tumors of the temporal lobe.
  Saygi S, Spencer SS, Scheyer R, Katz A, Mattson R, Epilepsia, 1/1/1992
• The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus.
  During M, Mattson R, Scheyer R, Rask C, Pierce M, McKelvy J, Thomas V, Epilepsia, 1/1/1992
• Functional characteristics of epileptogenic foci by EEG dipole modeling-interictal spikes.
  Ebersole JS, Scheyer RD, Pacia SV, Parks BJ, Wade PB, Electroencephalogr Clin Neurophysiol, 1/1/1992
• Antiepileptic drug pharmacology in epilepsy surgery patients by in vivo microdialysis.
  Scheyer RD, During MJ, Mattson RH, Toftness BR, Hochholzer JM, Cramer JA, Epilepsia, 1/1/1991
• Stability of epileptiform spike sources assessed by moving dipole analysis of EEG.
  Ebersole JS, Wade PB, Parks BJ, Scheyer RD, Epilepsia, 1/1/1991
• Carbamazepine concentrations and adverse effects.
  Cramer JA, Scheyer RD, Hochholzer JS, Mattson RH, and the VA Epilepsy Cooperative Study No. 264 Group, Epilepsia, 1/1/1991
• Diagnosis of seizure precipitants using medication monitors.
  Cramer JA, Mattson RH, Scheyer RD, Neurology, 1/1/1991
• Population based estimation of time-variant pharmacokinetics.
  Scheyer RD, Cramer JA, Mattson RH, & VA Epilepsy Coop 118 Group, Clin Pharmacol Ther, 1/1/1991
• Bayesian non-steady state phenytoin predictions: The effect of parallel elimination pathways.
  Scheyer RD, Clin Pharmacol Ther, 1/1/1990
• Valproate related tremor.
  Scheyer RD, Cramer JA, Toftness BR, Mattson RH, Epilepsia, 1/1/1989
• Join now to see all

Lectures

• Informing Early Development Decisions 
  San Francisco, CA - 1/1/2014
• Comparative Trials: Lessons from Beyond Oncology 
  Boston, MA - 1/1/2011
• Role of Biomarkers in Early Clinical Phase Decisions. 
  Philadelphia, PA - 1/1/2007
• MRI in MS Clinical Trials. 
  Berlin, Germany - 1/1/2005
• Translating CNS activity to the Clinic: Optimizing the Interface. 
  Amsterdam, Netherlands - 1/1/2005
• Utility of Clinical Models for Connecting Discovery and Development 
  London, UK - 1/1/2004
• Phase II: Attrition and Innovation. 
  Washington, DC - 1/1/2003
• Adapting clinical trial concepts to pre-clinical studies. 
  London, UK - 1/1/2003
• Developing Clinical Models for Compound Screening in CNS Drug Development. 
  Philadelphia, PA - 1/1/2002
• Imaging in CNS Pharmaceutical Development: Surrogate marker or pretty picture? 
  London, UK - 1/1/2001
• Relevant measures of drug concentration in the brain. 
  Washington, DC - 1/1/2000
• Ictal PET. 
  San Francisco, CA - 1/1/1996
• Involvement of glutamate in human epileptic activities. 
  Oslo, Norway - 1/1/1996
• Pharmacokinetic studies in man-brain compartment. 
  Sydney, Australia - 1/1/1995
• Computer models in pharmacology: Models for dosage prediction. 
  1/1/1994
• Kinetics/ Dynamics of Antiepileptic Drugs in Man: Intracerebral microdialysis and magnetic resonance spectroscopy. 
  1/1/1994
• Brain concentrations of antiepileptic drugs: Methodological considerations. 
  1/1/1992
• Non-steady-state estimation of phenytoin concentrations. 
  Rockville, MD - 1/1/1990
• Join now to see all